论文部分内容阅读
目的观察罗格列酮对糖耐量受损(IGT)合并代谢综合征(MS)患者脂肪细胞因子如脂联素、超敏C反应蛋白(hsC-RP)、肿瘤坏死因子α(TNF-α)、白介素6(IL-6)的影响。方法对2004年10月至2005年1月南京鼓楼医院内分泌门诊53例新诊断IGT(7.8mmol/L≤餐后2h血糖<11.1mmol/L)合并代谢综合征患者,随机采用罗格列酮和治疗性生活方式干预,比较两组治疗前和治疗12周后上述细胞因子浓度变化。结果罗格列酮组较治疗性生活方式干预组血糖、血脂明显下降,胰岛素抵抗明显改善,脂联素明显增加,IL-6、TNF-α、hsC-RP明显降低(P<0.01)。结论(1)罗格列酮可明显改善MS患者的胰岛素抵抗;(2)罗格列酮能增加脂联素的表达,降低hsCRP、TNF-α、IL-6的浓度,改善MS患者的血管炎症反应。
Objective To observe the effects of rosiglitazone on adipokines such as adiponectin, hsC-RP and TNF-α in patients with impaired glucose tolerance (IGT) and metabolic syndrome (MS) , Interleukin 6 (IL-6). Methods From October 2004 to January 2005, 53 newly diagnosed IGT patients (7.8mmol / L≤2.1hour postprandial blood glucose <11.1mmol / L) with metabolic syndrome in the endocrinology clinic of Nanjing Drum Tower Hospital were randomized to receive either rosiglitazone and The treatment of sexual lifestyle intervention, compared two groups before treatment and after 12 weeks of treatment of the above cytokine concentration changes. Results Compared with the therapeutic lifestyle intervention group, the levels of blood glucose and blood lipids in rosiglitazone group were significantly decreased, insulin resistance was significantly improved, adiponectin was significantly increased, IL-6, TNF-α and hsC-RP were significantly decreased (P <0.01). Conclusions (1) Rosiglitazone can significantly improve insulin resistance in MS patients. (2) Rosiglitazone can increase the expression of adiponectin, decrease the concentration of hsCRP, TNF-α and IL-6, and improve the blood vessels of MS patients Inflammation.